Blueprint Medicines
BPMC
£96.94
Share price
0.00%
Change (1 day)
12.78%
Change (1 year)
Categories
Earnings for Blueprint Medicines (BPMC)
Earnings in 2025 (TTM): -£0.12 Billion
According to Blueprint Medicines 's latest financial reports the company's current earnings are £0.56 Billion. In 2024 the company made an earning of -£49.32 Million, an increase over its 2023 earnings that were of -£0.38 Billion. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Blueprint Medicines from 2014 to 2025
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2025 (TTM)  | -£0.12 Billion | 142.49% |
| 2024 | -£49.32 Million | -86.98% |
| 2023 | -£0.38 Billion | -8.38% |
| 2022 | -£0.42 Billion | -13.85% |
| 2021 | -£0.49 Billion | -304.94% |
| 2020 | £0.23 B | -189.97% |
| 2019 | -£0.27 Billion | 46.93% |
| 2018 | -£0.18 Billion | 59.76% |
| 2017 | -£0.12 Billion | 104.32% |
| 2016 | -£54.29 Million | 37.38% |
| 2015 | -£39.52 Million | 30.99% |
| 2014 | -£30.17 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Isoray
ISR | -£8.16 Million | -92.92% | 🇺🇸 USA |
 OPKO Health
OPK | -£0.42 Million | -99.64% | 🇺🇸 USA |
 Pacific Biosciences
PACB | -£0.5 Billion | 327.39% | 🇺🇸 USA |
 Acceleron Pharma XLRN | -£0.2 Billion | 66.02% | 🇺🇸 USA |